Quick Facts

• Primary Use: Supports the management of megaloblastic anemia linked to folate deficiency.
• Supportive Use: Recommended to help reduce the risk of certain fetal abnormalities, such as neural tube defects, when taken before and during early pregnancy.

---

Fertifol is a medication indicated for the therapeutic management of megaloblastic and macrocytic anemias that are confirmed to be due to folate deficiency. Folate is a B-vitamin that is required by the body to assist in the synthesis of genetic material and the proper maturation of red blood cells.

The medication is also utilized to help women who are capable of becoming pregnant meet the recommended daily intake of folic acid. Supplementation is specifically advised in the periconceptional period—the time shortly before and after conception—as this approach helps to reduce the risk of the developing fetus experiencing certain serious birth defects affecting the brain and spine, known as neural tube defects (NTDs). Adequate intake is essential for proper cell division and growth during this crucial stage of development.

In clinical settings, this preparation may also be used to help address deficiencies that arise from certain medication regimens or medical conditions.

Fertifol (Folic Acid) eligibility is defined by regulatory bodies based on the need for supplementation and critical safety checks to prevent adverse outcomes.

Contraindications (Must Not Use)

Condition/Population	Restriction Type
Untreated Cobalamin (Vitamin B12) Deficiency	Absolute Contraindication for long-term therapy, as Folic Acid can mask hematological symptoms while irreversible neurological damage progresses (FDA; SmPC).
Hypersensitivity	Prohibited for patients with a known allergy to Folic Acid or any component (SmPC).
Malignant Disease	Generally should not be used, unless a megaloblastic anemia due to folate deficiency is confirmed (SmPC).

---

Eligibility and Conditional Use

• Allowed Use: Folic Acid is explicitly recommended for women of childbearing potential and pregnant women to help prevent Neural Tube Defects (CDC; FDA). Use is also allowed during lactation and for patients with confirmed folate-deficient anemia (SmPC).
• Conditional Use: If a Vitamin B12 deficiency is present, Folic Acid must not be given alone; it requires concurrent treatment with Vitamin B12 (SmPC). Patients with a seizure disorder or those on certain anticonvulsant drugs require monitoring due to potential reduced drug effectiveness (FDA; SmPC).
• Age-Related Eligibility: The medicine is generally established for adults, and specific doses are defined for pediatric populations. For older adults, official guidance recommends that a B12 absorption test be considered before starting long-term therapy (SmPC).

Interaction Map: Interactions with other medicines and products — official regulatory information for Fertifol

Interaction scope

Category	Details
Medicinal product categories with documented interactions	Folic Acid Antagonists, Anticonvulsants (Hydantoins, Barbiturates), Bile Acid Sequestrants, Cytostatic Agents, Certain Antibacterials.
Specific interacting medicines (if explicitly listed)	Phenytoin, Phenobarbital, Methotrexate, Chloramphenicol, Cholestyramine, Fluorouracil, Sulfasalazine, Oral Zinc, Trimethoprim, Pyrimethamine.
Mechanistic basis of interactions	Pharmacological antagonism (with folic acid antagonists). Reduction of serum levels (of anticonvulsants). Interference with absorption.
Timing-based interaction rules	Cholestyramine: Folic Acid must be administered at least 1 hour before or 4 to 6 hours after the sequestrant. Antacids (aluminum or magnesium): Must not be taken within 2 hours of Folic Acid administration.
Population-specific interaction notes	None documented where the severity of a major interaction is formally restricted to a specific patient population.
Interaction-related restrictions	Co-administration with anticonvulsants is associated with a risk of reduced anticonvulsant effects. Co-administration with high-dose Folic Acid and Fluorouracil may increase the toxicity of Fluorouracil.

---

Interaction classifications (high-level)

Category	Classification Details
Interaction severity classification	Interactions are defined as major/highly clinically significant (e.g., with Phenytoin) or moderate (e.g., absorption interference), which mandates specific administration schedules.
Regulatory basis	The data is based on multiple government regulatory sources, including EMA and FDA Prescribing Information.

---

Resulting interaction structure

Official interaction statements:

• Folic Acid administration is documented to reduce the serum levels of certain antiepileptic drugs, including phenytoin, which may lead to diminished anticonvulsant action.
• Co-administration with folic acid antagonists (e.g., Methotrexate) may result in a mutual inhibition of their respective pharmacological effects.
• The intestinal absorption of Folic Acid may be reduced by various agents, including Cholestyramine, Sulfasalazine, and Alcohol.
• Chloramphenicol may interfere with folate metabolism and is documented to hinder the hematopoietic response to Folic Acid therapy.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define Folic Acid's interaction profile across two primary outcomes: an impact on the exposure and effect of co-administered medicines (such as reducing anticonvulsant levels) and a reduction in Folic Acid's own bioavailability due to absorption interference. These statements establish specific constraints on co-administration, requiring dose separation for certain drugs and carrying cautions regarding the potential for antagonistic effects or altered drug exposure.

Enzyme-Driven Activation and Coenzyme Generation

Fertifol's mechanism is purely metabolic and initiates with the synthetic molecule Folic Acid acting as a substrate for the enzyme Dihydrofolate Reductase (DHFR). DHFR performs the necessary reduction steps, converting Folic Acid into the biologically functional coenzyme, Tetrahydrofolate (THF), and its derivatives. This action contributes to the generation of the intracellular pool of active coenzymes utilized in fundamental metabolic reactions.

---

Fueling DNA Synthesis and Cell Replication

Active THF derivatives are indispensable cofactors in One-Carbon Metabolism, supporting the de novo creation of purines and thymidylate. This molecular action enables the synthesis of components for DNA synthesis and repair, facilitating the mitotic rate of precursor cells in systems like the bone marrow (Erythropoiesis).

---

Influencing Homocysteine Homeostasis

A specific active folate derivative, 5-methyltetrahydrofolate, acts as a methyl donor to the enzyme Methionine Synthase. This interaction drives the remethylation of Homocysteine back into the essential amino acid Methionine. This process influences cellular resource recycling and systemic metabolic regulation.

How to Use Fertifol: Administration Guidelines

Fertifol, which contains Folic Acid, is administered according to standardized regimens. The medicine is primarily intended for oral administration as a film-coated tablet and does not require specialized preparation or dilution before use.

---

Standard Dosing and Frequency

Standard dosing is determined by the specific use pattern, and administration is generally once daily (OD). The tablets should be swallowed whole with water, and it is suggested to take them before meals.

Use Pattern	Standard Labeled Dosing	Required Duration / Timing
Periconceptional Supplementation	0.4 mg (400 micrograms) daily	Begins at least one month prior to conception and continues throughout the entire first trimester (12 weeks) of pregnancy.
Therapeutic Deficiency Management	5 mg daily	Continues until the hematological picture is normalized, which is typically for four months.

---

Administration Context and Adjustments

The usage protocol is based on the specific clinical scenario. The primary preventive use relies on the precise temporal constraint of starting before conception. For children (1–18 years) with folate-deficient megaloblastic anemia, dosing may also be set at 5 mg daily for four months, with potential subsequent maintenance adjustments. The medicine is generally used in an outpatient setting, and parenteral administration is reserved for cases of impaired absorption.

Research Evidence / Overview of Studies for Fertifol (Folic Acid)

The available research base for the active ingredient in Fertifol, folic acid, has been extensively evaluated by health organizations. The body of evidence is often grouped into two primary areas: the management of nutritional deficiencies and the ability of supplementation to influence the occurrence of certain birth defects. This overview describes the type of studies conducted and what the research suggests, without offering advice or clinical recommendations.

---

Evidence for Managing Folate Deficiency Anemia

This section summarizes the available research, including metabolic investigations and clinical observation studies, which explored folic acid in the context of megaloblastic or macrocytic anemia due to a confirmed deficiency.

The research describes patterns where providing folic acid replacement was associated with shifts in hematological markers toward values seen in non-anemic populations. Findings across these clinical settings describe consistent patterns regarding the measured changes in blood cell features following replacement therapy. Given that this process is a form of nutritional replacement for a known deficiency, a lack of modern, large-scale, placebo-controlled clinical trials are not fully established, as testing replacement therapy against a placebo is often not considered necessary or ethically feasible.

---

Evidence for Influencing Neural Tube Defects (NTDs)

This part of the overview will outline the structure of research based on trials and systematic reviews that have examined the association between folic acid supplementation and the risk of birth defects affecting the fetal brain and spine. The primary outcome axis was the incidence of NTDs in the offspring.

For women who have not previously experienced an NTD-affected pregnancy, large international Randomized Controlled Trials (RCTs) and subsequent meta-analyses reported patterns where the measured NTD incidence differed between groups receiving folic acid supplementation and control groups. These studies included women planning or starting pregnancy. The findings contribute to the broader evidence landscape used to inform public health guidance regarding the association between supplementation and NTD occurrence.

Research for Secondary Prevention of NTDs

Studies explored the recurrence rate of NTDs in the high-risk population of women who have already had one affected pregnancy. Research describes patterns where the measured NTD recurrence rate differed in the groups receiving supplementation, although study populations in this area were limited due to the lower incidence of recurrence.

Common questions about Fertifol (FAQ)

---

Q: Is Fertifol the same as other folic acid supplements?

A: Fertifol contains the active ingredient Folic Acid, which is the precise synthetic form of Vitamin B9 found in many other generic and branded supplements. According to official prescribing information, while the active ingredient is identical, the specific tablet formulation and the exact dosage may vary between different commercial products.

Q: Can Fertifol be taken long-term?

A: Regulatory documents caution that Folic Acid should not be taken alone for long periods without assessment for an underlying Vitamin B12 deficiency. Long-term use of Folic Acid alone may mask the blood changes (hematological symptoms) of a B12 deficiency, which could permit the progressive and irreversible development of severe neurological complications if the B12 deficiency remains uncorrected.

Q: Are there any studies on Fertifol for non-pregnancy related uses?

A: Yes, the active ingredient, Folic Acid, is documented in official sources for other uses. these include managing folate-deficient megaloblastic anemia and use in certain combination products to address conditions such as anemia associated with iron deficiency.

Q: Are there any common interactions between Fertifol and herbal supplements?

A: Official patient information generally advises discussing the use of herbal remedies or supplements with a healthcare professional before starting treatment. Separately, oral zinc is listed in some regulatory texts as a mineral supplement that may reduce Folic Acid absorption.

Q: How does Fertifol compare to similar products in terms of absorption?

A: According to official pharmacokinetic studies, Folic Acid is the stable, synthetic form of folate that is rapidly absorbed from the small intestine. This results in peak plasma levels being generally reached within one hour of an oral dose.

Q: Is the research evidence for Fertifol considered high-quality?

A: The evidence base used to support public health guidance includes large, international Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These are specific study designs that contribute to the strong evidence landscape used to inform public health guidance.

Q: Can Fertifol be used during breastfeeding?

A: Official regulatory texts confirm that Folic Acid is actively excreted into human breast milk. Studies suggest that when Folic Acid is used according to the instructions, the medicine poses minimal risk to the infant during the period of breastfeeding.

Q: Is Fertifol a single-ingredient drug?

A: Fertifol contains Folic Acid as the sole active ingredient. However, the finished tablet formulation also contains inactive ingredients (known as excipients), which may include components like lactose monohydrate or magnesium stearate, as documented in official prescribing information.

Q: What are the official guidelines regarding the use of Fertifol?

A: Official public health guidelines generally recommend Folic Acid supplementation for all women of childbearing potential to reduce the risk of certain birth defects, known as Neural Tube Defects (NTDs). These guidelines indicate that use should begin prior to conception.

Q: Is Fertifol available in liquid form?

A: The active ingredient, Folic Acid, is available in various dosage forms, which may include oral tablets, injections, or oral solutions/liquids, depending on the specific product and the country's official approvals for that preparation.

Q: Can teenagers use Fertifol?

A: Yes. Regulatory and public health guidance includes specific daily recommended amounts for both male and female teenagers for general supplementation. For the treatment of a confirmed deficiency, doses are determined individually based on official guidelines.

Q: How quickly does Fertifol start working?

A: Pharmacokinetic studies indicate that Folic Acid is absorbed relatively quickly after taking an oral dose. Folic Acid begins to appear in the plasma approximately 15 to 30 minutes after ingestion, with peak plasma levels generally reached within one hour.

Q: Are there any common side effects from taking Fertifol?

A: Side effects from Folic Acid are generally described in regulatory texts as uncommon or rare. The most frequently reported non-serious effects include gastrointestinal disturbances (such as flatulence or nausea) and mild skin reactions (like rash or itching).

Q: Is it normal to feel nauseous after starting Fertifol?

A: While nausea is listed as a reported gastrointestinal side effect, regulatory documents state that this effect is associated with higher doses over long periods. Information regarding consumption with or after a meal is sometimes provided in patient leaflets.

Q: Can I take Fertifol with an antacid?

A: Certain antacids, specifically those containing aluminum or magnesium, may reduce the amount of Folic Acid absorbed. Regulatory instructions specify that Folic Acid should not be taken within 2 hours before or after these types of antacids.

Q: Is it necessary to take Fertifol with food?

A: Official administration regimens may suggest taking the tablet before meals. However, patient information often suggests taking it with or just after a meal or snack as a way to help alleviate potential nausea.

Q: What happens if I miss a dose of Fertifol?

A: The standard regulatory-linked guidance for a missed dose is to take it as soon as you remember. If the time is almost right for the next scheduled dose, the guidance indicates to skip the missed dose and wait for the next regularly scheduled dose.

Q: Is Fertifol safe for people with certain allergies?

A: Official patient information advises that people should inform a healthcare professional if they have ever had an allergic reaction to Folic Acid or any other medicines, foods, dyes, or preservatives. This information is used to comply with official safety precautions.

Q: What should I do if I suspect a severe side effect from Fertifol?

A: Official guidance states that if a severe or serious side effect is suspected, a person should contact their doctor or pharmacist immediately or seek emergency medical attention. This guidance applies to any severe allergic reactions.

Q: Why is the mechanism of action important for this type of supplement?

A: The mechanism is described as important because Folic Acid functions as an essential cofactor for enzymes involved in creating DNA and RNA. This process is vital for cell growth and repair and is especially relevant during periods of rapid cell division, such as in pregnancy planning.

Q: Does Fertifol contain lactose?

A: Specific regulatory documents for Folic Acid tablets list lactose monohydrate as an inactive ingredient. Patients with known hereditary problems of lactose intolerance are officially cautioned against taking this medicine.

Q: What is the shelf life of Fertifol?

A: The official regulatory documentation for the product specifies a shelf life, which is typically listed as 36 months from the date of manufacture. This shelf life is valid only if the product is stored according to the specified conditions.

Q: Can I crush or chew the Fertifol tablet?

A: Official administration guidelines state that the film-coated tablets should be swallowed whole with water. The instructions do not describe a process for the tablets to be crushed or chewed.

Q: Is it possible to take too much Fertifol?

A: If a person takes more Folic Acid tablets than prescribed, the regulatory guidance states it is unlikely to cause any harm. However, if concerned about a high dose, the regulatory guidance indicates that a healthcare professional should be contacted if concerned.

Q: Do other medicines affect how Fertifol works in the body?

A: Yes, some agents are documented to interfere with Folic Acid’s absorption or metabolism. For example, certain anti-tuberculosis medicines and alcohol are noted in regulatory documents to reduce the intestinal absorption of Folic Acid, which can lessen the amount available for the body to utilize.

Q: How long does Fertifol stay in your system?

A: Pharmacokinetic studies show that the majority of Folic Acid's metabolic products appear in the urine after 6 hours, and elimination is generally complete within 24 hours of an oral dose. The elimination half-life has been reported to be approximately 1.5 hours.

Q: Does Fertifol affect blood test results?

A: Regulatory-linked warnings note that if a patient is taking certain antibiotics (such as tetracycline), this may result in false low serum or red cell folate levels when measured in laboratory tests.

Q: Is Fertifol commonly used in fertility treatments?

A: Folic Acid is officially recommended for women of childbearing potential, with use beginning prior to conception, to reduce the risk of certain birth defects. This specified pre-conception period of supplementation is referred to in official documents as periconceptional supplementation.

Q: Are there different strengths or versions of Fertifol available?

A: Regulatory documents establish different strengths for Folic Acid, such as 0.4 mg and 5 mg tablets, which are intended for different official uses (preventive vs. therapeutic). The ingredient is also widely available in multi-ingredient combination products.

How to Store and Dispose of Fertifol?

Regulatory documents specify strict storage conditions to maintain the stability and quality of Folic Acid tablets (Fertifol).

Official Storage Requirements

Item	Requirement
Temperature	Store at controlled room temperature: 20 C to 25 C.
Protection	Must be protected from light and protected from moisture.
Container	Keep in the original container, which should be kept tightly closed.
Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medicinal product must be disposed of in accordance with local regulatory requirements. Official instructions explicitly state that the tablets must not be thrown away via wastewater or household waste.